Skip to content

ASCELIA
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

En
Sv

About us
- Management
- Board of Directors
Therapeutic areas
- Liver metastases
- Gastric Cancer
Pipeline
- Orviglance®
- Oncoral
Partnering
Investors
Governance
Career
- Open positions
- Our values
Contact

« All Events

This event has passed.

Interim Report 9M 2024

Name: Interim Report 9M 2024
Start: 2024-11-07T00:00:00+01:00
End: 2024-11-07T23:59:59+01:00

November 7

« Ascelia Pharma – Final outcome of rights issue with HC Andersen
Presentation of Q3 2024 results »

Google Calendar
iCalendar
Outlook 365
Outlook Live

Details

Date:: November 7

« Ascelia Pharma – Final outcome of rights issue with HC Andersen
Presentation of Q3 2024 results »

Learn more

Start (en)
Calendar
Event

About us

Start (en)
About us
Career
Contact
Privacy policy
About cookies
Cookie settings
IMPORTANT INFORMATION

Pipeline

Oncoral
Orviglance^®

IR & Media

Subscribe to press releases
Press releases & News
Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance^® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Video

Cookies

We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy

Settings Accept all

Cookies

Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.

Save Accept all

Interim Report 9M 2024

November 7

Details

About us

Contact

Our values